Vaxcyte, Inc. (PCVX) stock
PCVXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$68.62+2.26 (+3.41%)
Close on Nov 11, 2026Market cap $10.21BP/E –Yield 0.00%
Vaxcyte total assets
Total assets on the balance sheet at the end of each period.
Vaxcyte's total assets was $2.99B at Sep 30, 2026. For fiscal 2025 it was $3.00B, down 14.5% from the year before. The highest annual figure on record is $3.51B in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.00B | -14.5% |
| FY2024 | Dec 31, 2024 | $3.51B | +149.4% |
| FY2023 | Dec 31, 2023 | $1.41B | +39.9% |
| FY2022 | Dec 31, 2022 | $1.01B | +210.2% |
| FY2021 | Dec 31, 2021 | $324.34M | -17.4% |
| FY2020 | Dec 31, 2020 | $392.83M | +497.9% |
| FY2019 | Dec 31, 2019 | $65.70M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.99B | -5.8% |
| Q2 FY2026 | Jun 30, 2026 | $3.14B | -5.1% |
| Q1 FY2026 | Mar 31, 2026 | $3.35B | -0.9% |
| Q4 FY2025 | Dec 31, 2025 | $3.00B | -14.5% |
| Q3 FY2025 | Sep 30, 2025 | $3.17B | -10.9% |
| Q2 FY2025 | Jun 30, 2025 | $3.31B | +58.4% |
| Q1 FY2025 | Mar 31, 2025 | $3.38B | +61.5% |
| Q4 FY2024 | Dec 31, 2024 | $3.51B | +149.4% |
| Q3 FY2024 | Sep 30, 2024 | $3.56B | +137.9% |
| Q2 FY2024 | Jun 30, 2024 | $2.09B | +38.9% |
| Q1 FY2024 | Mar 31, 2024 | $2.09B | +107.4% |
| Q4 FY2023 | Dec 31, 2023 | $1.41B | +39.9% |
| Q3 FY2023 | Sep 30, 2023 | $1.50B | +263.1% |
| Q2 FY2023 | Jun 30, 2023 | $1.50B | +265.1% |
| Q1 FY2023 | Mar 31, 2023 | $1.01B | +150.3% |
| Q4 FY2022 | Dec 31, 2022 | $1.01B | +210.2% |
| Q3 FY2022 | Sep 30, 2022 | $412.07M | +16.4% |
| Q2 FY2022 | Jun 30, 2022 | $411.62M | +15.0% |
| Q1 FY2022 | Mar 31, 2022 | $402.72M | +5.3% |
| Q4 FY2021 | Dec 31, 2021 | $324.34M | -17.4% |
| Q3 FY2021 | Sep 30, 2021 | $354.07M | -12.3% |
| Q2 FY2021 | Jun 30, 2021 | $358.05M | -14.0% |
| Q1 FY2021 | Mar 31, 2021 | $382.35M | +482.0% |
| Q4 FY2020 | Dec 31, 2020 | $392.83M | – |
| Q3 FY2020 | Sep 30, 2020 | $403.82M | – |
| Q2 FY2020 | Jun 30, 2020 | $416.25M | – |
| Q4 FY2019 | Dec 31, 2019 | $65.70M | – |
See a number that looks wrong?